Null Cell Adenomas of the Pituitary Gland: an Institutional Review of Their Clinical Imaging and Behavioral Characteristics
Tóm tắt
The aim of the study was to establish if the null cell adenoma (NCA) forms a distinct subgroup with unique clinicopathological characteristics within the nonfunctioning pituitary adenoma group particularly in relation to the silent gonadotroph adenomas (SGAs). We identified 31 patients with the pathological diagnosis of NCA verified by routine histology and immunohistochemistry with distinct differentiation from SGAs by an established negative testing for SF-1 at the Toronto Western Hospital between December 2004 and August 2010. We reviewed their demographic data, clinical features, magnetic resonance imaging, and the histologic variables: MIB-1, FGFR4, and P27. We compared these to 63 SGAs identified within the same period. All the NCAs were macroadenomas with diameter ranging from 15—57 mm and tumor volumes between 1.95–53.5 mm3. Preoperative cavernous sinus tumor growth was able to predict the presence of a residual after surgery (p = 0.023). Furthermore, preoperative cavernous sinus extension (p = 0.002) and negative P27 expression (p = 0.035) were able to independently predict the subsequent growth of the postoperative tumor residual. Comparing the NCA to SGA, we found that MIB-1 was higher in NCA (mean ± SD = 3.43 ± 2.76 %) compared to SGAs (mean ± SD = 2.49 ± 1.41 %) (p = 0.044). The preoperative and postoperative tumor volume doubling times (TVDTs) displayed a negative correlation in the SGA (r = −0.855, p = 0.002) while in the NCA, a positive correlation was evident (r = 0.718, p = 0.029). Our study suggests that the NCAs are a distinct group with differing behavioral characteristics from the SGAs. It also appears that the finding of cavernous sinus extension on preoperative imaging and a negative P27 expression on immunohistochemistry in NCAs may be valuable tools in predicting residual tumor growth which may impact on postoperative care.
Tài liệu tham khảo
Asa SL, Ezzat S (2009) The pathogenesis of pituitary tumors. Annual review of pathology 4: 97–126
Greenman Y, Stern N (2009) Non-functioning pituitary adenomas. Best Practice & Research Clinical Endocrinology & Metabolism 23: 625–638
Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapcer Z, Young WF, Meyer FB, Kuroki T, Riehle DL, Laws ER (2006) Pathobiology of Pituitary Adenomas and Carcinomas. Neurosurgery 59: 341–353
Mahta A, Haghpanah V, Lashkari A, Heshmat R, Larijani B, Tavangar SM (2007) Non-functioning pituitary adenoma: immunohistochemical analysis of 85 cases. Folia neuropathologica/Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences 45: 72–77
Bujawansa S, Thondam SK, Steele C, Cuthbertson DJ, Gilkes CE, Noonan C, Bleaney CW, Macfarlane IA, Javadpour M, Daousi C (2014) Presentation, management and outcomes in acute pituitary apoplexy: a large single-centre experience from the United Kingdom. Clinical endocrinology 80: 419–424
Mete O, Asa SL (2012) Clinicopathological correlations in pituitary adenomas. Brain pathology (Zurich, Switzerland) 22: 443–453
Al-Brahim NYY, Asa SL (2006) My approach to pathology of the pituitary gland. Journal of Clinical Pathology 59: 1245–1253
Asa SL (2008) Practical pituitary pathology: what does the pathologist need to know? Archives of pathology & laboratory medicine 132: 1231–1240
Miller BA, Rutledge WC, Ioachimescu AG, Oyesiku NM (2012) Management of large aggressive nonfunctional pituitary tumors: experimental medical options when surgery and radiation fail. Neurosurg Clin N Am 23: 587–594
Alahmadi H, Lee D, Wilson JR, Hayhurst C, Mete O, Gentili F, Asa SL, Zadeh G (2012) Clinical features of silent corticotroph adenomas. Acta Neurochir (Wien) 154: 1493–1498
Chen L, White WL, Spetzler RF, Xu B (2011) A prospective study of nonfunctioning pituitary adenomas: presentation, management, and clinical outcome. Journal of neuro-oncology 102: 129–138
Ramirez C, Cheng S, Vargas G, Asa SL, Ezzat S, Gonzalez B, Cabrera L, Guinto G, Mercado M (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. The Journal of clinical endocrinology and metabolism 97: 1745–1751
Monsalves E, Larjani S, Loyola Godoy B, Juraschka K, Carvalho F, Kucharczyk W, Kulkarni A, Mete O, Gentili F, Ezzat S, Zadeh G (2014) Growth patterns of pituitary adenomas and histopathological correlates. The Journal of clinical endocrinology and metabolism: jc20133054
Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33: 610–617; discussion 617–618
Kovacs K, Horvath E, Ryan N, Ezrin C (1980) Null cell adenoma of the human pituitary. Virchows Archiv A, Pathological anatomy and histology 387: 165–174
Gittoes NJ (1998) Current perspectives on the pathogenesis of clinically non-functioning pituitary tumours. The Journal of endocrinology 157: 177–186
Holm R (1995) Null cell adenomas and oncocytomas of the pituitary gland. Pathology, research and practice 191: 348–352
Asa SL, Ezzat S (1998) The cytogenesis and pathogenesis of pituitary adenomas. Endocrine reviews 19: 798–827
Yamada S, Asa SL, Kovacs K (1988) Oncocytomas and null cell adenomas of the human pituitary: morphometric and in vitro functional comparison. Virchows Archiv A, Pathological anatomy and histopathology 413: 333–339
Sano T, Yamada S (1994) Histologic and immunohistochemical study of clinically non-functioning pituitary adenomas: special reference to gonadotropin-positive adenomas. Pathology international 44: 697–703
Al-Shraim M, Asa SL (2006) The 2004 World Health Organization classification of pituitary tumors: what is new? Acta neuropathologica 111: 1–7
Young WF, Jr., Scheithauer BW, Kovacs KT, Horvath E, Davis DH, Randall RV (1996) Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Mayo Clinic proceedings 71: 649–656
Yamada S, Kovacs K, Horvath E, Aiba T (1991) Morphological study of clinically nonsecreting pituitary adenomas in patients under 40 years of age. Journal of neurosurgery 75: 902–905
Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni MR, Marzoli SB, Pieralli S, Giovanelli M (2008) Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. Journal of neurosurgery 108: 525–532
Greenman Y, Ouaknine G, Veshchev I, Reider G, II, Segev Y, Stern N (2003) Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clinical endocrinology 58: 763–769
Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C, Young J, Alexopoulou O, Maiter D, Chanson P (2010) Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. European journal of endocrinology/European Federation of Endocrine Societies 163: 193–200
Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Takano K, Sano T (2007) A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61: 580–584; discussion 584–585
Steno A, Bocko J, Rychly B, Chorvath M, Celec P, Fabian M, Belan V, Steno J (2014) Nonfunctioning pituitary adenomas: association of Ki-67 and HMGA-1 labeling indices with residual tumor growth. Acta Neurochir (Wien) 156: 451–461
Widhalm G, Wolfsberger S, Preusser M, Fischer I, Woehrer A, Wunderer J, Hainfellner JA, Knosp E (2009) Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. Journal of neurosurgery 111: 563–571
Matsuyama J (2012) Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables. Neurologia medico-chirurgica 52: 563–569
Nakabayashi H, Sunada I, Hara M (2001) Immunohistochemical analyses of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society 49: 1193–1194
Mizoue T, Kawamoto H, Arita K, Kurisu K, Tominaga A, Uozumi T (1997) MIB1 immunopositivity is associated with rapid regrowth of pituitary adenomas. Acta Neurochir (Wien) 139: 426–431; discussion 431–422
Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Monting J, Reincke M (2003) Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. Journal of neurosurgery 99: 674–679
Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T (1996) The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas. Acta Neurochir (Wien) 138: 1449–1455
Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R, Veglia F, Mortini P, Giovanelli M (2000) Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery 47: 1313–1318; discussion 1318–1319
Dubois S, Guyetant S, Menei P, Rodien P, Illouz F, Vielle B, Rohmer V (2007) Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. European journal of endocrinology/European Federation of Endocrine Societies 157: 141–147
Bamberger CM, Fehn M, Bamberger AM, Ludecke DK, Beil FU, Saeger W, Schulte HM (1999) Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. European journal of endocrinology/European Federation of Endocrine Societies 140: 250–255
Zhao D, Tomono Y, Nose T (1999) Expression of P27kip1 and Ki-67 in pituitary adenomas: an investigation of marker of adenoma invasiveness. Acta Neurochir (Wien) 141: 187–192
Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, Farrell WE, Claret FX, Grossman AB (2002) Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. The Journal of clinical endocrinology and metabolism 87: 2635–2643
Wolfsberger S, Wunderer J, Zachenhofer I, Czech T, Bocher-Schwarz HG, Hainfellner J, Knosp E (2004) Expression of cell proliferation markers in pituitary adenomas—correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha. Acta Neurochir (Wien) 146: 831–839